Evidence map›Paper›PMID 36035204›Full record

ArticleOxidative medicine and cellular longevity2022

Qinbaohong Zhike Oral Liquid Attenuates LPS-Induced Acute Lung Injury in Immature Rats by Inhibiting OLFM4.

Fangbo Zhang, Yu Li, Yujie Xi, Yi Zhang, Lifang Wang, He Xu, Jixiang Tian, FeiFei Guo, Hongjun Yang

Abstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fangbo ZhangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0001-5426-0324
Yu LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yujie XiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yi ZhangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Lifang WangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
He XuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Jixiang TianInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
FeiFei GuoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0003-3624-4704
Hongjun YangExperimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0001-5501-3288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute respiratory infections (ARIs) are a common public safety threat with high morbidity and mortality in pediatric patients worldwide. Qinbaohong Zhike oral liquid (QBH), a marketed traditional Chinese medicine product, has been widely used to cure respiratory diseases. QBH is reported to have antitussive, expectorant, and antiasthmatic properties. However, its treatment effect against ARIs is not elucidated. This study aimed to explore the therapeutic efficacy of QBH in the treatment of ARIs-induced pneumonia. Network pharmacology was used to predict the possible targets of QBH against ARIs. Next, the tracheal lipopolysaccharide (LPS-)-induced acute lung injury (ALI) immature rat model was constructed to evaluate the therapeutic effect of QBH. Tandem mass tag (TMT-)-based quantitative proteomics was then used to screen the in-depth disease targets of QBH. QBH exerted a protective effect against LPS-induced ALI by inhibiting pulmonary pathological damage. QBH also reduced the levels of interleukin (IL)-6, tumor necrosis factor (TNF)-

Indexed as

Acute Lung InjuryLipopolysaccharidesAnimalsGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHumansInterleukin-6LungProteomicsRatsTumor Necrosis Factor-alphaGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-6LipopolysaccharidesOLFM4 protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID36035204
PMCPMC9400428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.